P110 activation protein is strongly expressed in intestinal fibrosis in inflammatory bowel disease patients

Autor: D Lartey, M van Roest, J Verhoeff, J Grootjans, C Buskens, J van der Bilt, M Wildenberg, G D'Haens, M Löwenberg

Publikováno v: Journal of Crohn's and Colitis. 17:i273-i276

Background Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) with limited diagnostic modalities to detect and determine the degree of fibrosis. Fibroblast activation protein alpha (FAP) is a protein with both dipeptidyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::929e71f448f2dec87bb05b17c7a67b95
https://doi.org/10.1093/ecco-jcc/jjac190.0240

P185 Global perception of normal life by healthcare professionals and IBD patients: mind the gap

Autor: J Van Oostrom, S Anjie, M Braad, J Horrigan, N Karimi, B Adi, G Ganesh, S K Yang, J Lasa, C Broër, A de Kruif, P Olivera Sendra, B D Ye, R Banerjee, S Connor, C Siegel, L Peyrin-Biroulet, K Gecse, G D'Haens

Publikováno v: Journal of Crohn's and Colitis. 17:i337-i339

Background For patients living with inflammatory bowel diseases (IBD), the ultimate treatment goal is “normal life”. However, no patient-reported outcome measurement (PROM) exists to measure the level of life normality in IBD. We previously asked

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e013f0f8b9e9b3b0255e6c3796416c79
https://doi.org/10.1093/ecco-jcc/jjac190.0315

OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results

Autor: G D'Haens, J Tran, S Danese, D T Rubin, N Aoyama, A Lügering, J Klaff, S Xuan, D Ilo, Y Sanchez Gonzalez, J Panes

Publikováno v: Journal of Crohn's and Colitis. 17:i27-i29

Background Abdominal pain (AP), bowel urgency (BU), stool frequency (SF), rectal bleeding (RB) and fatigue are debilitating symptoms that reduce quality of life in patients with ulcerative colitis (UC). Results from two Phase 3 induction trials and o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26ea7a0f84780ca2fea3ae29f95e9d30
https://doi.org/10.1093/ecco-jcc/jjac190.0020

P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies

Autor: R Atreya, P Irving, M Fujiya, J F Colombel, S Danese, L Peyrin-Biroulet, T Bessissow, R Panaccione, G D’Haens, S van Haaren, E Neimark, J Zambrano, Y Zhang, K Kligys, M Ferrante

Publikováno v: Journal of Crohn's and Colitis. 17:i675-i677

Background In the risankizumab (RZB) phase 3 clinical programme, Crohn’s disease (CD) patients who responded to RZB intravenous (IV) induction were re-randomised to RZB or placebo (PBO) (withdrawal PBO subcutaneous [SC] in maintenance (FORTIFY), wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84914133fddf23b45f465ef1cd068b55
https://doi.org/10.1093/ecco-jcc/jjac190.0678

Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases

Autor: Ashwin N Ananthakrishnan, Gilaad G Kaplan, Charles N Bernstein, Kristin E Burke, Paul J Lochhead, Alexa N Sasson, Manasi Agrawal, Jimmy Ho Tuan Tiong, Joshua Steinberg, Wolfgang Kruis, Flavio Steinwurz, Vineet Ahuja, Siew C Ng, David T Rubin, Jean-Frederic Colombel, Richard Gearry, M Abreu, V Ahuja, M Allez, A Ananthakrishnan, W Bemelman, C Bernstein, J Braun, Y Chowers, J-F Colombel, S Danese, G D'Haens, A D'Hoore, A Dignass, I Dotan, M Dubinsky, A Ekbom, P Fleshner, C Gasche, MA Gassull, R Gearry, S Ghosh, P Gibson, A Griffiths, J Halfvarson, S Hanauer, N Harpaz, A Hart, T Hibi, M Kamm, G Kaplan, A Kaser, B Korelitz, P Kotze, I Koutroubakis, W Kruis, P Lakatos, J Lewis, J Lindsay, E Loftus, E Louis, M Lukas, F Magro, U Mahadevan, G Mantzaris, J-Y Mary, D McGovern, B Moum, P Munkholm, M Neurath, S Ng, C O'Morain, T Oresland, R Panaccione, J Panes, Y Panis, J Pemberton, L Peyrin-Biroulet, C Prantera, D Rachmilewitz, Z Ran, W Reinisch, F Remzi, J Rhodes, R Riddell, G Rogler, D Rubin, D Sachar, W Sandborn, B Sands, B Sartor, J Schoelmerich, S Schreiber, C Siegel, B Siegmund, M Silverberg, J Söderholm, A Sood, A Spinelli, E Stange, F Steinwurz, S Targan, S Travis, D Turner, C Tysk, M Vatn, S Vermeire, M Watanabe, T Yamamoto, J Yamamoto-Furusho

Publikováno v: Ananthakrishnan, A N, Kaplan, G G, Bernstein, C N, Burke, K E, Lochhead, P J, Sasson, A N, Agrawal, M, Tiong, J H T, Steinberg, J, Kruis, W, Steinwurz, F, Ahuja, V, Ng, S C, Rubin, D T, Colombel, J-F, Gearry, R & International Organization for Study of Inflammatory Bowel Diseases 2022, ' Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases : an International Organization for Study of Inflammatory Bowel Diseases consensus ', The Lancet Gastroenterology & Hepatology, vol. 7, no. 7, pp. 666-678 . https://doi.org/10.1016/S2468-1253(22)00021-8

Environmental and lifestyle factors play an important role in the natural history of Crohn's disease and ulcerative colitis. A group of international experts from the International Organization for the Study of Inflammatory Bowel Diseases voted on a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f58298ce6a08ab88218f15d73ca467
https://doi.org/10.1016/s2468-1253(22)00021-8